Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study

Do disease-modifying antirheumatic drugs and non-steroidal anti-inflammatory drugs increase the burden on ankylosing spondylitis patients with mild-moderate COVID-19? evidence from a retrospective cohort study

Objectives: The impact of non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and tumor necrosis factor inhibitors (TNFi) on the outcomes of mild-moderate COVID-19 in patients with ankylosing spondylitis (AS) remains unclear. This s...

Full description

Bibliographic Details
Main Authors: Yan Li, Zhengyuan Hu, Yufei Guo, Zheng Zhao, Kunpeng Li, Xiuru Wang, Jie Zhang, Dongfeng Liang, Jianglin Zhang, Xiaoyue Hu, Jian Zhu, Feng Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Pharmacology
Subjects:
coronavirus disease 2019 (COVID-19)
ankylosing spondylitis
TNF-inhibitor
DMARDs (synthetic)
cohort study
NSAID (non-steroidal anti-inflammatory drug)
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1266915/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1266915/full

Similar Items